A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy
NCT ID: NCT05669638
Last Updated: 2024-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
80 participants
OBSERVATIONAL
2023-05-01
2025-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* The autoantibody profile of patients
* The adverse reactions of patients
* The changes of immune cells and cytokine in patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs
NCT03984318
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
NCT04283539
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967
Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors
NCT04268368
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
NCT04242095
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* The autoantibody profile of patients
* The adverse reactions of patients
* The changes of immune cells and cytokine in patients (e.g., T cell, B cell, IL-6, etc.)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Receiving anti-PD1 immunotherapy
Exclusion Criteria
2. Functional impairment of immune system caused by other diseases or other reasons, such as Systemic lupus erythematosus (SLE), AIDS, etc.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xuanwu Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hongyan Li, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Xuanwu Hospital, Beijing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xuanwu Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
hongyanli1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.